| Literature DB >> 32119894 |
Alan Menter1, Joel M Gelfand2, Cody Connor3, April W Armstrong4, Kelly M Cordoro5, Dawn M R Davis6, Boni E Elewski3, Kenneth B Gordon7, Alice B Gottlieb8, Daniel H Kaplan9, Arthur Kavanaugh10, Matthew Kiselica11, Dario Kivelevitch1, Neil J Korman12, Daniela Kroshinsky13, Mark Lebwohl14, Craig L Leonardi15, Jason Lichten11, Henry W Lim16, Nehal N Mehta17, Amy S Paller18, Sylvia L Parra19, Arun L Pathy20, Elizabeth Farley Prater21, Robert S Rahimi1, Reena N Rupani14, Michael Siegel22, Benjamin Stoff23, Bruce E Strober24, Elliot B Tapper25, Emily B Wong26, Jashin J Wu27, Vidhya Hariharan28, Craig A Elmets3.
Abstract
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).Entities:
Keywords: Clinical guidelines for psoriasis; dermatology; nonbiologic systemic; psoriasis; psoriasis guidelines; skin disease
Year: 2020 PMID： 32119894 DOI： 10.1016/j.jaad.2020.02.044
Source DB: PubMed Journal: J Am Acad Dermatol ISSN： 0190-9622 Impact factor: 11.527